{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:49:46Z","timestamp":1794412186744,"version":"4.9.0"},"reference-count":83,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Non-small cell lung cancer (NSCLC) is characterized by substantial molecular heterogeneity that critically influences the efficacy of immunotherapy. Although immune checkpoint inhibitors (ICIs) have improved outcomes in selected patients, responses vary markedly across molecular subtypes defined by targetable driver gene alterations. Increasing evidence indicates that oncogenic drivers, including\n                    <jats:italic>EGFR<\/jats:italic>\n                    ,\n                    <jats:italic>ALK<\/jats:italic>\n                    ,\n                    <jats:italic>KRAS<\/jats:italic>\n                    ,\n                    <jats:italic>MET<\/jats:italic>\n                    ,\n                    <jats:italic>RET<\/jats:italic>\n                    , and\n                    <jats:italic>BRAF<\/jats:italic>\n                    , actively shape the tumor immune microenvironment (TIME) by regulating antigen presentation, immune cell infiltration, cytokine signaling, metabolic programs, and immune checkpoint expression. These interactions generate distinct driver gene\u2013associated immune phenotypes that underlie differential sensitivity and resistance to ICIs. Recent advances in single-cell and spatial profiling have further revealed the complexity and spatial organization of these immune landscapes. In this review, we summarize current mechanistic and clinical evidence supporting the targetable driver gene\u2013TIME axis in NSCLC and discuss its implications for immunotherapy response, resistance, and patient stratification. This integrative framework provides a rationale for precision immunotherapy strategies and the design of biomarker-driven clinical trials.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1801943","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T05:25:09Z","timestamp":1776317109000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Targetable driver gene\u2013tumor immune microenvironment axis in non-small cell lung cancer: from molecular pathological mechanisms to precision immunotherapy stratification strategies"],"prefix":"10.3389","volume":"17","author":[{"given":"Wenqing","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Affiliated Hospital of Shandong University of Traditional Chinese Medicine","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengyan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Qingdao Traditional Chinese Medicine Hospital (Haici Hospital)","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29030150","article-title":"Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology","volume":"29","author":"Mithoowani","year":"2022","journal-title":"Curr Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1203539","article-title":"Cryoablation and immunity in non-small cell lung cancer: a new era of cryo-immunotherapy","volume":"14","author":"Velez","year":"2023","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"100878","DOI":"10.1016\/j.lanepe.2024.100878","article-title":"NSCLC: bridging the gap between clinical progress and real-world application","volume":"38","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"B4","doi-asserted-by":"publisher","first-page":"103119","DOI":"10.1016\/j.critrevonc.2020.103119","article-title":"Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma","volume":"156","author":"Lamberti","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)01029-8","article-title":"New promises and challenges in the treatment of advanced non-small-cell lung cancer","volume":"404","author":"Meyer","year":"2024","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.32604\/or.2024.045356","article-title":"Targeting KRAS in pancreatic cancer","volume":"32","author":"Stickler","year":"2024","journal-title":"Oncol Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.04.003","article-title":"Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn","volume":"16","author":"Qiao","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/cas.16428","article-title":"Persist or resist: Immune checkpoint inhibitors in EGFR-mutated NSCLC","volume":"116","author":"Zhu","year":"2025","journal-title":"Cancer Sci"},{"key":"B9","doi-asserted-by":"publisher","first-page":"102602","DOI":"10.1016\/j.ctrv.2023.102602","article-title":"Immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: A systematic review","volume":"119","author":"Attili","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"B10","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s40164-024-00543-1","article-title":"Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies","volume":"13","author":"Zheng","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.20517\/cdr.2025.14","article-title":"Tumor microenvironment-driven resistance to immunotherapy in non-small cell lung cancer: strategies for Cold-to-Hot tumor transformation","volume":"8","author":"Yu","year":"2025","journal-title":"Cancer Drug Resist"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.02.012","article-title":"Spatial immunophenotyping of the tumour microenvironment in non-small cell lung cancer","volume":"185","author":"Backman","year":"2023","journal-title":"Eur J Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1084887","article-title":"Towards a consensus definition of immune exclusion in cancer","volume":"14","author":"Tiwari","year":"2023","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s10555-025-10272-4","article-title":"Shaping the battlefield: EGFR and KRAS tumor mutations' role on the immune microenvironment and immunotherapy responses in lung cancer","volume":"44","author":"Alsaed","year":"2025","journal-title":"Cancer Metastasis Rev"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.pccm.2024.08.002","article-title":"Overcoming EGFR-TKI resistance by targeting the tumor microenvironment","volume":"2","author":"Zhang","year":"2024","journal-title":"Chin Med J Pulm Crit Care Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2024.2372327","article-title":"Characterizing the immune tumor microenvironment in ALK fusion-positive lung cancer: state-of-the-art and therapeutical implications","volume":"20","author":"Sposito","year":"2024","journal-title":"Expert Rev Clin Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012288","article-title":"Genetic drivers of tumor microenvironment and immunotherapy resistance in non-small cell lung cancer: the role of KEAP1, SMARCA4, and PTEN mutations","volume":"13","author":"Paredes","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"8402","DOI":"10.1038\/s41467-025-63465-4","article-title":"Oncogenic driver mutations underlie the spatial tumour immune landscape of non-small cell lung cancer","volume":"16","author":"Hartner","year":"2025","journal-title":"Nat Commun"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.02.012","article-title":"Exploiting the therapeutic implications of KRAS inhibition on tumor immunity","volume":"42","author":"Molina-Arcas","year":"2024","journal-title":"Cancer Cell"},{"key":"B20","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12943-025-02287-w","article-title":"Single-cell and spatial transcriptomic analyses revealing tumor microenvironment remodeling after neoadjuvant chemoimmunotherapy in non-small cell lung cancer","volume":"24","author":"Cui","year":"2025","journal-title":"Mol Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"4388","DOI":"10.1038\/s41467-024-48700-8","article-title":"Single-cell and spatial transcriptomics analysis of non-small cell lung cancer","volume":"15","author":"DeZuani","year":"2024","journal-title":"Nat Commun"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1649445","article-title":"Integrative profiling of lung cancer biomarkers EGFR, ALK, KRAS, and PD-1 with emphasis on nanomaterials-assisted immunomodulation and targeted therapy","volume":"16","author":"Peng","year":"2025","journal-title":"Front Immunol"},{"key":"B24","article-title":"EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)","volume":"5","author":"Midha","year":"2015","journal-title":"Am J Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01441-6","article-title":"Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations","volume":"81","author":"Mok","year":"2021","journal-title":"Drugs"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3309","article-title":"The ERBB network: at last, cancer therapy meets systems biology","volume":"12","author":"Yarden","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.35.6345","article-title":"ROS1 rearrangements define a unique molecular class of lung cancers","volume":"30","author":"Bergethon","year":"2012","journal-title":"J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.07.004","article-title":"Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers","volume":"13","author":"Drilon","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(17)30679-4","article-title":"Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial","volume":"18","author":"Planchard","year":"2017","journal-title":"Lancet Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-15-2061","article-title":"MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis","volume":"22","author":"Tong","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","year":"2014","journal-title":"Nature"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.04.001","article-title":"AKT\/PKB Signaling: Navigating the Network","volume":"169","author":"Manning","year":"2017","journal-title":"Cell"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/nature23643","article-title":"CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity","volume":"549","author":"Burr","year":"2017","journal-title":"Nature"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210421","article-title":"MAP kinase signalling pathways in cancer","volume":"26","author":"Dhillon","year":"2007","journal-title":"Oncogene"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2024.01.009","article-title":"Targeting MHC-I inhibitory pathways for cancer immunotherapy","volume":"45","author":"Wang","year":"2024","journal-title":"Trends Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"5505","DOI":"10.1038\/s41467-021-25728-8","article-title":"MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I","volume":"12","author":"Bragelmann","year":"2021","journal-title":"Nat Commun"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-3284","article-title":"MAPK Pathway Mutations Emerge in Mutant IDH1 Inhibitor-Resistant Cholangiocarcinoma and Attenuate the IFN Response","volume":"32","author":"Wan","year":"2026","journal-title":"Clin Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2012.03.014","article-title":"JAK and STAT signaling molecules in immunoregulation and immune-mediated disease","volume":"36","author":"O'Shea","year":"20112","journal-title":"Immunity"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-16-2554","article-title":"Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma","volume":"23","author":"Dong","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0179-8","article-title":"Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy","volume":"19","author":"Skoulidis","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.4427","article-title":"Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis","volume":"4","author":"Lee","year":"2018","journal-title":"JAMA Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23126489","article-title":"EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment","volume":"23","author":"Madeddu","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.844866","article-title":"Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response","volume":"13","author":"Taylor","year":"2022","journal-title":"Front Immunol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1186\/s12967-024-05456-5","article-title":"EGFR mutations induce the suppression of CD8(+) T cell and anti-PD-1 resistance via ERK1\/2-p90RSK-TGF-\u03b2 axis in non-small cell lung cancer","volume":"22","author":"Huang","year":"2024","journal-title":"J Transl Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2023.11.007","article-title":"Metabolic interplay: tumor macrophages and regulatory T cells","volume":"10","author":"Vilbois","year":"2024","journal-title":"Trends Cancer"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1556209","article-title":"The role of tumor-associated macrophages in lung cancer","volume":"16","author":"Zhu","year":"2025","journal-title":"Front Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009165","article-title":"Understanding the dynamics of TKI-induced changes in the tumor immune microenvironment for improved therapeutic effect","volume":"12","author":"Lu","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02746-z","article-title":"KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma","volume":"131","author":"Budczies","year":"2024","journal-title":"Br J Cancer"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14145135","article-title":"Prognostic Impact of KRAS-TP53 Co-Mutations in Patients with Early-Stage Non-Small Cell Lung Cancer: A Single-Center Retrospective Study","volume":"14","author":"Motta","year":"2025","journal-title":"J Clin Med"},{"key":"B56","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s11864-021-00891-8","article-title":"Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy","volume":"22","author":"Mazzaschi","year":"2021","journal-title":"Curr Treat Options Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.arbres.2024.06.021","article-title":"NRF2 Signaling Pathway in Chemo\/Radio\/Immuno-Therapy Resistance of Lung Cancer: Looking Beyond the Tip of the Iceberg","volume":"60","author":"Ramisetti","year":"2024","journal-title":"Arch Bronconeumol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-025-03560-4","article-title":"NRF2 immunobiology in cancer: implications for immunotherapy and therapeutic targeting","volume":"44","author":"Panda","year":"2025","journal-title":"Oncogene"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1649468","article-title":"Single-cell and spatial transcriptomics integration: new frontiers in tumor microenvironment and cellular communication","volume":"16","author":"Shi","year":"2025","journal-title":"Front Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003534","article-title":"Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma","volume":"10","author":"Yang","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.82317","article-title":"CXCL12-CXCR4\/CXCR7 Axis in Cancer: from Mechanisms to Clinical Applications","volume":"19","author":"Yang","year":"2023","journal-title":"Int J Biol Sci"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.06.014","article-title":"Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer","volume":"35","author":"Di Federico","year":"2024","journal-title":"Ann Oncol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s43046-024-00207-5","article-title":"PD-L1 expression and its significance in advanced NSCLC: real-world experience from a tertiary care center","volume":"36","author":"Kilaru","year":"2024","journal-title":"J Egypt Natl Canc Inst"},{"key":"B64","doi-asserted-by":"publisher","first-page":"e2311181","DOI":"10.1001\/jamanetworkopen.2023.11181","article-title":"Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy","volume":"6","author":"Aggarwal","year":"2023","journal-title":"JAMA Netw Open"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003087","article-title":"Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better","volume":"10","author":"Zheng","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.3390\/cancers17061027","article-title":"Tumor Heterogeneity and the Immune Response in Non-Small Cell Lung Cancer: Emerging Insights and Implications for Immunotherapy","volume":"17","author":"Oh","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B67","article-title":"Overview of Systematic Reviews of ICIs in NSCLC With EGFR, ALK, ROS1, and RET Actionable Driver Mutations: Drugs","volume-title":"Canadian Agency for Drugs and Technologies in Health","year":"2024"},{"key":"B68","doi-asserted-by":"publisher","first-page":"101106","DOI":"10.1016\/j.currproblcancer.2024.101106","article-title":"Current perspectives of KRAS in non-small cell lung cancer","volume":"51","author":"Harris","year":"2024","journal-title":"Curr Probl Cancer"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.2147\/ott.S381825","article-title":"Molecular Characteristics and the Effect of KRAS Mutation on the Prognosis of Immunotherapy in Non-Small Cell Lung Cancer in Xinjiang, China","volume":"15","author":"Gu","year":"2022","journal-title":"Onco Targets Ther"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.05.015","article-title":"MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma","volume":"41","author":"Qian","year":"2023","journal-title":"Cancer Cell"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002891","article-title":"Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer","volume":"9","author":"Negrao","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17142388","article-title":"Co-Occurring Genomic Alterations in NSCLC: Making Order into a Crowded List","volume":"17","author":"Attili","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076710","article-title":"The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors","volume":"24","author":"Moeckel","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14031025","article-title":"NSCLC: Current Evidence on Its Pathogenesis, Integrated Treatment, and Future Perspectives","volume":"14","author":"Tahayneh","year":"2025","journal-title":"J Clin Med"},{"key":"B75","doi-asserted-by":"publisher","first-page":"e0283719","DOI":"10.1371\/journal.pone.0283719","article-title":"Identifying optimal first-line immune checkpoint inhibitors based regiments for advanced non-small cell lung cancer without oncogenic driver mutations: A systematic review and network meta-analysis","volume":"18","author":"Liu","year":"2023","journal-title":"PLoS One"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-008818","article-title":"Immunotherapy-based regimens for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR-TKI therapy","volume":"12","author":"Qin","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"B78","doi-asserted-by":"publisher","first-page":"189194","DOI":"10.1016\/j.bbcan.2024.189194","article-title":"Perioperative immunotherapy for patients with EGFR mutant non-small cell lung cancer: Unexpected potential benefits","volume":"1879","author":"Teng","year":"2024","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32020110","article-title":"Perioperative Chemo-Immunotherapy in Non-Oncogene-Addicted Resectable Non-Small Cell Lung Cancer (NSCLC): Italian Expert Panel Meeting","volume":"32","author":"de Marinis","year":"2025","journal-title":"Curr Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(24)00379-6","article-title":"Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis","volume":"25","author":"Zhao","year":"2024","journal-title":"Lancet Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.04.005","article-title":"Machine learning-based immune phenotypes correlate with STK11\/KEAP1 co-mutations and prognosis in resectable NSCLC: a sub-study of the TNM-I trial","volume":"34","author":"Rakaee","year":"2023","journal-title":"Ann Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26136348","article-title":"PD-L1 Expression and Comprehensive Genomic Profiling in Advanced NSCLC: A Single-Centre Experience","volume":"26","author":"Gurevi\u010dien\u0117","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-23-4027","article-title":"Combining Genomic Biomarkers to Guide Immunotherapy in Non-Small Cell Lung Cancer","volume":"30","author":"van de Haar","year":"2024","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1801943\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T05:25:10Z","timestamp":1776317110000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1801943\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":83,"alternative-id":["10.3389\/fimmu.2026.1801943"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1801943","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"article-number":"1801943"}}